Genentech, Amgen Face Big Impact From Part B International Pricing Index
Medicare spending on Genentech’s Rituxan and Lucentis, and Amgen’s Neulasta and Prolia/Xgeva, would have been $3.8bn less in 2016 using the proposed international pricing index model, CMS estimates.
You may also be interested in...
Unique NDCs, Medicare reimbursement codes would allow for lower list prices for the drugs when used in combination for lung cancer, Genentech says.
Manufacturers refute Administration claims that Medicare International Pricing Index model will have minimal impact on industry innovation.
Mandatory nature of demonstration might hamper progress of new model for changing Medicare Part B drug reimbursement, as it did when Obama Administration tried it.